Merrill keeps Serono at buy

Serono SA retained its buy rating from Merrill Lynch analyst Erica Whittaker. The company took itself off the market due to low offers. Merrill believes this news will disappoint the market. The analyst also believes that Rebif's multiple sclerosis market leadership will not be significantly impacted by the impending return of Tysabri. Shares of the Geneva, Switzerland, biotechnology company were down $1.83, or 10.37%, at $15.81 on volume of 499,600 shares versus the three-month running average of 199,808 shares. (NYSE: SRA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.